论文部分内容阅读
目的:初步探讨Septin 9作为大B细胞淋巴瘤化疗敏感性相关标志物的实验依据。方法:通过肿瘤药物敏感试验选取化疗高敏感性和低敏感性大B细胞淋巴瘤组织,进行蛋白质组学比较研究后得出差异表达蛋白;对在低敏感组中高表达的Septin 9进一步行Western Blot验证,应用免疫组化技术检测Septin 9在临床病例中的表达情况。结果:化疗高敏感性和低敏感性大B细胞淋巴瘤组织蛋白质组学比较研究显示Septin 9蛋白在高敏感组表达低于低敏感组,免疫印迹和免疫组化结果与蛋白质组结果是一致的。结论:Septin 9蛋白表达在化疗敏感性不同大B细胞淋巴瘤中存在差别,存在化疗敏感性越高Septin 9表达越低的趋势,可能作为预测淋巴瘤化疗敏感性的候选标志物。
Objective: To investigate the experimental basis of Septin 9 as a marker of chemosensitivity in large B cell lymphoma. Methods: Chemotherapy-sensitive large B-cell lymphoma tissues were selected for tumor chemosensitivity test. Differentially expressed proteins were obtained by comparative proteomics study. Septin 9 highly expressed in the low sensitive group was further subjected to Western Blot Validation, the application of immunohistochemical detection of Septin 9 in clinical cases. Results: A comparative proteomic study of chemotherapy-sensitive and low-sensitivity large B-cell lymphoma showed that Septin 9 protein expression was lower in the hypersensitivity group than in the low-sensitivity group. The results of Western blotting and immunohistochemistry were consistent with those of the proteome . CONCLUSIONS: The expression of Septin 9 is different in chemosensitivity different large B cell lymphoma. The higher the sensitivity of chemotherapy, the lower the expression of Septin 9 may be as a candidate marker for predicting chemosensitivity of lymphoma.